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BACKGROUND: Cross-talk between receptor tyrosine kinases and the oestrogen receptor (ER) is implicated in resistance to endocrine
therapy. We investigated whether AEE788 (a combined inhibitor of EGFR, HER2 and VEGFR) plus tamoxifen or letrozole enhanced
the individual anti-tumour effects of these agents.
METHODS: Breast cancer cell lines modelling endocrine-resistant and -sensitive disease were engineered to express aromatase (A) and
examined using proliferation, western blotting and ER-a transcription assays.
RESULTS: AEE788 enhanced the anti-proliferative effect of tamoxifen and letrozole in ER
þ cell lines (MCF-7 2A, ZR75.1 A3 and
BT474 A3). This associated with an elevated G1 arrest and nuclear accumulation of p27. It is noteworthy that AEE788 alone or in
combination with endocrine therapy increased the expression of progesterone receptor (PGR) and TFF1 in BT474 A3 cells. This may
indicate a mechanism of resistance to AEE788 in ER
þ/HER2
þ breast cancers. In a ZR75.1 A3 xenograft, AEE788 alone or
in combination with tamoxifen provided no further benefit compared with letrozole. However, letrozole plus AEE788 produced
a significantly greater inhibition of tumour growth compared with letrozole alone.
CONCLUSION: These data suggest that AEE788 plus letrozole in breast cancer overexpressing HER2 may provide superior anti-tumour
activity, compared with single agents.
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Over 70% of breast cancers at primary diagnosis express the
oestrogen receptor (ER) and require oestrogen (E) for their
growth. This has been exploited clinically by the development of
endocrine agents such as tamoxifen and aromatase inhibitors
(AIs). Recent studies suggest that AIs are superior to tamoxifen in
early and advanced breast cancer (Goss et al, 2005; Howell et al,
2005). Despite advances in the efficacy of AIs, a large proportion of
women eventually relapse with endocrine-resistant disease.
Clinical studies suggest that expression of HER2 is associated
with a decreased response to tamoxifen (Dowsett et al, 2001;
Gutierrez et al, 2005; Arpino et al, 2007). Similarly, although
neoadjuvant letrozole (AI) is clinically effective in ER
þ/HER2
þ
tumours in the short term, long-term treatment is asso-
ciated with increased tumour proliferation. This implies that
therapeutic resistance to AIs in patients with ER
þ/HER2
þ breast
cancer may manifest later in the clinical course of the disease
(Ellis et al, 2006).
In vitro and in vivo models of endocrine-resistant breast cancer
allude to a cross-talk between the ER and the receptor tyrosine kinase
(RTK) signal transduction pathways. This allows the ER to
circumvent the need for steroid hormone because of either ligand-
independent activation or downregulation of ER genomic function
(Arpino et al,2 0 0 8 ;M a s s a r w e het al, 2008). Studies suggest that the
use of specific receptor tyrosine kinase inhibitors (RTKi) can
suppress the proliferation of endocrine-resistant cells (Martin et al,
2003; Shou et al, 2004; Chu et al, 2005) and restrict the onset of
resistance (Gee et al, 2003, Arpino et al, 2007). This provides a strong
rationale for the combined use of endocrine agents with RTKi.
AEE788 is a combined inhibitor of EGFR/HER2 and VEGFR
tyrosine kinases and has been shown to inhibit the proliferation of
EGFR- and HER2-overexpressing cell lines (Traxler et al, 2004). On
the basis of these data, our aims were (1) to determine whether
AEE788, in combination with endocrine therapy, could provide
superior therapeutic efficacy both in vitro and in vivo compared
with monotherapy and (2) to identify any significant molecular
changes associated with treatment, which may have clinical
implications.
As our focus was the inhibitory effect of AEE788 on HER2, we
selected a panel of breast cancer cell lines with naturally varying
ER and HER2 expression levels that modelled endocrine-resistant
and -sensitive disease. These were engineered to express aroma-
tase, allowing the analysis of letrozole, tamoxifen and AEE788 in
clinically reflective models.
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Primary antibodies such as phosphorylated and total ERK1/2,
AKT, p27, ER-a Ser
118 and total cyclin D1 were purchased from
Cell Signaling Inc, Hitchin, Hertfordshire, UK; total ER (6F11)
was from Novacastra Laboratories Ltd, Milton Keynes,
Buckinghamshire, UK; and actin (AC-20) was purchased from
Sigma, Poole, Dorset, UK; aromatase (MCA2077S) was purchased
from AbDSeroTec (Oxford, UK). Secondary antibodies such as
anti-mouse and anti-rabbit HRP were obtained from Amersham
Pharmacia (Little Chalfont, Nottinghamshire, UK). 17b-estradiol
(E2) and 4-hydroxytamoxifen (4-OH tamoxifen) were obtained
from Sigma. Letrozole and AEE788 were synthesised within the
laboratories of Novartis Pharma AG (Basel, Switerland).
Tissue culture
MCF-7, ZR75.1, BT474 and SKBR3 cell lines expressing aromatase
or control backbone (neo) were maintained in phenol red
containing RPMI 1640 medium plus 2mM glutamine, 10mgml
 1
insulin, 10% (v/v) fetal bovine serum (FBS) and 1mgml
 1 G418.
For all experiments, cell lines were deprived of steroids for 3 days
before seeding by culturing in phenol-red-free RPMI 1640
supplemented with 10% (v/v) dextran-coated charcoal-stripped
FBS (DCC-FBS) (Darbre et al, 1983).
Real-time quantitative reverse transcriptase PCR
Gene expression was assessed using a TaqMan ABI 7900 (Applied
Biosystems, Warrington, Cheshire, UK) as described previously
(Martin et al, 2005). The sequences of the primer/probe sets were
as follows: PGR: forward 50-ACCTGAGGCCGGATTCAGAA-30,
reverse, 50CCACAGGTAAGGACACCATAATGAC-30,p r o b e ,5 0FAM-
CCAGAGCCCACAATACAGCTTCGAGTCATT-TAMRA-p-30;T F F 1 ,
forward 50-GCCCAGACAGAGACGTGTACAG-30,r e v e r s e5 0GTCGA
AACAGCAGCCCTTATTT-30,p r o b e ,5 0FAM-CCCCCGTGAAAGACA
GAATTGTGGTTT-TAMR-p-30; ESR1: forward, 50-TTCTTCAAGAG
AAGTATTCAAGGACATAAC-30,r e v e r s e5 0-TCGTATCCCACCTTTC
ATCATTC-30,p r o b e ,5 0FAM-CCAGCCACCAACCAGTGCACCAT-T
AMRA-p-30; GAPDH was used as the housekeeping gene to
normalise the data.
Cell proliferation assays
Aromatase (A) and control (neo) cell lines were seeded into 12-well
plates at c.1 10
4 cells per well for MCF-7, ZR75.1, SKBR3 and
4 10
4 for BT474. Monolayers were treated with a combination of
drugs for 6 days. Cell number was determined using a Z1 Coulter
Counter (Beckman Coulter, High Wickham, UK). The interaction
between AEE788 and 4-OH tamoxifen or letrozole was analysed by
the median effect plot method described by Chou and Talalay
(1984). Calculation of the combination index (CI) took into
account a non-fixed drug ratio and was based on the assumption
that the action of the two drugs was mutually non-exclusive for the
strict detection of synergism. A CI o1 indicates synergism, CI¼1
indicates additive and a CI 41 indicates antagonism.
Transcription assay
Cell lines were seeded in 24-well plates at 7 10
4 cells per well in
DCC medium for all cell lines except BT474, which was seeded
at 1 10
5 cells per well. After 24h, monolayers were transfected
by Fugene (Roche, Burgess Hill, West Sussex, UK) with 0.1mgo f
EREIItkluc and 0.1mg of pCH110 overnight, before treatment with
the drugs indicated. After treatment for 24h, luciferase (Promega,
Southampton, Hampshire, UK) and b-galactosidase (Galacton Star,
PE Biosystems, Warrington, Cheshire, UK) activity levels were
measured using a luminometer.
Preparation of whole-cell extracts for immunoblots
Cell monolayers were harvested as described previously (Martin et al,
2003), resolved by SDS polyacrylamide gel electrophoresis and
transferred to nitrocellulose filters (Schleicher and Schuell, GE
Healthcare Maidstone, Kent, UK). Filters were probed with the specific
antibodies indicated, as described previously (Martin et al, 2003).
Cell-cycle effects of AEE788, alone or in combination
with endocrine agents
Cells were seeded into 10cm dishes, allowed to acclimatise
overnight and then transferred to serum-free medium for 24h.
Monolayers were then treated with drug combinations for 72h.
Cells were fixed and stained with propidium iodide. Cell-cycle
analysis was carried out using fluorescence-activated cell sorting
(Martin et al, 2007).
Apoptosis assay
Apoptosis was measured with a Cell Death Detection ELISA
PLUS kit (Roche) according to the manufacturer’s instructions.
Cells were seeded into 12-well plates at a density of 1 10
5 cells per
well. After 24h, the cells were transferred to serum-free medium
overnight, and thereafter treated for 24h with drug combinations.
Human tumour xenografts
Experiments were carried out according to Home Office guidelines
and after obtaining approval of the Institute of Cancer Research
Ethics Committee. Ovariectomised female Ncr Foxhead nude mice
were kept under sterile conditions (six per cage) with free access to
food and water. The ZR75.1 A3 cell line was grown as subcutaneous
xenografts by passage of 2mm diameter pieces of tumour. Growth
was maintained by intradermal injection of an androstenedione
pellet (dose 1.5mg over 60 days; Innovative Research of America,
Sarasota, FL, USA). Once tumours reached a diameter of B7mm,
mice were randomised to receive vehicle (10% N-methyl-pyrolli-
done (NMP)/90% polyethylene glycol (PEG300), AEE788
(6.7mgml
 1 in 10% NMP/90% PEG300), tamoxifen (3.3mgml
 1
in 10% NMP/90% PEG300)), letrozole (0.17mgml
 1 in 10% NMP/
90% PEG300) or AEE788±tamoxifen or letrozole. All drugs were
administered daily by oral gavage for a total of 24 days. Tumour
growth was assessed twice weekly by caliper measurements of the
two largest diameters. Volumes were then calculated according to
the formula a b
2 p/6, where a and b are orthogonal tumour
diameters. Tumour volumes were then expressed as percentage
change in volume at the start of treatment (day 0).
Statistical analysis
Data are presented as ±s.e.m. Differences in the mean of two
samples were analysed using Student’s unpaired t-test, with
differences o0.05 being considered significant. For the xenograft
study, overall statistical difference was calculated using the
Kruskal–Wallis test and statistical differences between individual
treatment arms were calculated using the Mann–Whitney test.
Repeated measures analysis using multilevel modelling with time as
a linear predictor was undertaken in SPSS (SPSS Inc, Woking,
Surrey, UK). Ln ((volume at time t)/(volume at baseline)) was used
as the outcome. Between-mouse variation was treated as a random
effect, and linear and quadratic effects for the time effect, including
interactions with treatment, were used.
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Generation and characterisation of Arom-transfected
cell lines
Human breast cancer cell lines with varying endogenous
expression levels of ER and HER2 (MCF-7 (ER
þ, HER2
 ),
ZR75.1 (ER
þ, HER2
þþ), BT474 (ER
þ, HER2
þþþ), SKBR3
(ER
 , HER2
þþþ)) were genetically engineered to express
aromatase (A) or the backbone vector (neo) (Banerjee et al,
2009) (Supplementary Figure 1). Treatment of cell lines expressing
aromatase with escalating concentrations of androstenedione
revealed a concentration-dependent increase in growth for ER
þ
MCF-7 A2, ZR75.1 A3 and BT474 A3, whereas ER
  SKBR3 A3
showed no change (Figure 1A). Control clones (neo) were
non-responsive to the proliferative effects of androstenedione.
4-OH tamoxifen showed a concentration-dependent decrease in
growth for MCF-7 A2 (IC50 10nM) and ZR75.1 A3 (IC50 10nM)
(Figure 1B). BT474 A3 cells were less sensitive with an
IC5041000nM, whereas SKBR3 A3 cells were unaffected. 4-OH
tamoxifen seemed to have a degree of agonist activity in ZR75.1
and BT474 neo controls, which was most marked in the MCF-7
neo cell line, an observation in keeping with previous studies
(Reddel and Sutherland, 1984). Escalating concentrations of
letrozole led to a concentration-dependent decrease in prolifera-
tion of all ER
þ cell lines with IC50 values of c.5nM for ZR75.1
A3 and MCF-7 A2. BT474 A3 cells were less sensitive with
an IC50 value of c.50nM. No effect on SKBR3 A3 was evident
(Figure 1C). Letrozole had no effect on the neo-expressing control
cell lines.
Both BT474 A3 and SKBR3 A3 (Figure 1D) were highly sensitive
to the growth-suppressive effects of AEE788 with IC50 values of
0.5mM and 1mM, respectively. ZR75.1 and MCF-7 neo- and
aromatase-expressing cells were less sensitive with IC50 values of
c.5mM, indicative of their lower HER2 expression (data shown
as colour figure in Supplementary Figure 2).
Effects of AEE788 alone or in combination with tamoxifen
or letrozole on HER2 and ER signalling
Target cell lines were treated with escalating concentrations of
4-OH tamoxifen or letrozole±a sub-optimal concentration of
AEE788 (ZR75.1 A3, MCF-7 A2 (2mM) and BT474 A3 (0.25mM)).
Combination with AEE788 resulted in a 10-fold increase in
sensitivity to 4-OH tamoxifen (IC50 10nM vs 1nM) for ZR75.1
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Figure 1 The effect of HER-2 and oestrogen receptor (ER) expressions on the growth response of breast tumour cell lines expressing aromatase to
various endocrine agents. (A) Breast tumour cell lines with varying ER and HER2 expression levels, transduced to express aromatase (CYP 19) (A) or the
back bone vector (neo), were treated with escalating concentrations of androstenedione. After 6 days of treatment, the cell number was established using a
coulter counter. Data are expressed as fold change compared with vehicle control. (B) The breast tumour cell lines were treated with log10(M) increasing
concentrations of 4-OH tamoxifen in the presence of 10nM androstenedione. (C) Cells were treated with log10(M) increasing concentrations of letrozole in
combination with a standard 10nM concentration of androstenedione. (D) Breast tumour cell lines were treated with increasing concentrations of AEE788
in combination with a standard concentration of androstenedione (10nM). Bars represent±s.e.m. The data are representative of five individual experiments.
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sA3 and a two-fold increase in sensitivity in MCF-7 A2 (IC50 10nM
vs. 5nM) (Figure 2A). Formal analysis showed CI o1, indicating a
synergistic relationship for AEE788 in combination with 4-OH
tamoxifen at concentrations of 1 and 10nM (CI 0.52 and 0.4,
respectively) in ZR75.1 A3 cells and at 10, 100 and 1000nM
(CI 0.26, 0.26 and 0.25, respectively) in MCF-7 2A. In BT474 A3,
which showed a reduced sensitivity to 4-OH tamoxifen, combina-
tion with AEE788 significantly lowered the IC50 value from
41000nM to 10nM with CI o1 at 10, 100 and 1000nM 4-OH
tamoxifen (CI 0.83, 0.85 and 0.84, respectively). As expected, 4-OH
tamoxifen alone or in combination with AEE788 had no effect on
the proliferation of the ER
  cell line SKBR3 A3.
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Figure 2 AEE788 functions synergistically with 4-hydroxytamoxifen (4-OH) tamoxifen or letrozole in ER
þ cell lines. (A)E R
þ cell lines MCF-7 A2 and
ZR75.1 A3 were treated with a standard concentration of androstenedione (10nM) and log10(M) increasing concentrations of 4-OH tamoxifen or
letrozole±AEE788 (2mM). After 6 days of treatment, the cell number was analysed using a coulter counter. (B) HER2
þ cell lines BT474 A3 and SKBR3 A3
were treated as described in A, with the exception that 0.25mM AEE788 was used in the combination. Bars represent ±s.e.m of triplicate wells. The data are
representative of three individual experiments. (C) The effect of the drugs alone or in combination was assessed by immunoblotting. BT474 A3 and MCF-7
A2 cells were deprived of steroids then treated with a standard concentration of androstenedione (10nM) alone or in combination with 4-OH tamoxifen
(10nM), letrozole (10nM) or AEE788 (5mM for MCF-7 A2, or 0.5mM for BT474 A3 cells). After 48h, whole-cell extracts were probed for the markers
indicated.
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letrozole (IC50 5nM to 1nM) when combined with AEE788 with a
CI o1 at letrozole concentrations of 0.1 and 1nM (CI 0.89 and 0.57,
respectively) (Figure 2B). Similarly, ZR75.1 A3 showed a 10-fold
increase in sensitivity (IC50 5nM to 0.5nM) with CI o1 with
letrozole concentrations of 1, 10 and 100nM (CI 0.145, 0.075 and
0.384, respectively). BT474 A3 cells were highly sensitive to the
combination, shifting the IC50 value for letrozole to almost 50-fold
(IC50 50nM vs 1n M) with a CI o1 for letrozole concentrations of 1,
10 and 100nM (CI 0.67, 0.37 and 0.36, respectively).
Assessment of the HER2 downstream signal transduction
pathways showed that AEE788±either endocrine agent had little
effect on HER2 phosphorylation at Tyr 1248 in either MCF-7 A2 or
BT474 A3 (Figure 2C). However, both pERK1/2 and pAKT were
suppressed. Whereas ER-a protein levels were reduced by the
addition of androstenedione in both cell lines, AEE788 in
combination with 4-OH tamoxifen or letrozole increased ER-a
expression.
Effects of AEE788 in combination with endocrine
treatment on cell-cycle progression
As both ERK1/2 and AKT are intricately involved in cell growth,
we investigated the effect of AEE788±endocrine therapy on cell-
cycle progression (Figure 3A). As changes in the percentage of cells
in G2/M were only modest, we focused our analysis on S-phase and
G1-phase alterations. Androstenedione significantly increased the
number of MCF-7 A2 cells in S-phase to 13% compared with the
steroid-depleted control (3.6%, P¼0.0004). Treatment with either
4-OH tamoxifen or letrozole decreased this to 9% (P¼0.006) and
10% (P¼0.008), respectively. The combination of AEE788 with
4-OH tamoxifen or letrozole reduced this further compared with
monotherapies (6.4 vs 9%, P¼0.05; and 7.44 vs 10%, P¼0.005).
In contrast, BT474 A3 cells showed no significant difference in
the number of cells in S-phase in control vs androstenedione.
Treatment with AEE788±androstenedione significantly reduced
the number of cells in S-phase (9.9 vs 2.24%, P¼0.035; and
9.1 vs 5.37%, P¼0.003). 4-OH tamoxifen caused an increase in G1
(70 vs 76%, P¼0.05), whereas letrozole seemed most effective
(70 vs 79.3%, Po0.001). AEE788 in combination with endocrine
therapy further reduced the proportion of cells in S-phase
compared with endocrine agents alone (AEE788þ4-OH tamoxifen
2.4%, Po0.001; letrozoleþAEE788 2%, Po0.001) (Figure 3B).
However, there was no significant increase in G1 when comparing
4-OH tamoxifen±AEE788. In contrast, letrozoleþAEE788 in-
creased the percentage of cells in G1 (79.3 vs 83.4%, P¼0.005). It is
noteworthy that the addition of AEE788 seemed to significantly
increase the number of cells in sub-G1, suggesting the fact that it
may induce apoptosis particularly in the BT474 A3 cell line.
We next investigated alterations in cyclin D1 and p27
kip1
(Figure 3C). In BT474 A3 cells, cyclin D1 was suppressed
significantly by AEE788±endocrine agents compared with
androstenedione alone. MCF-7 A2 cells revealed modest changes
in cyclin D1, although AEE788 alone or plus letrozole seemed
superior. p27
kip1 expression in MCF-7 2A cells was unchanged with
either 4-OH tamoxifen or letrozole. However, AEE788 alone or
combined with letrozole showed a marked increase in p27
kip1.I n
BT474 A3 cells, AEE788±letrozole or 4-OH tamoxifen induced
greater increases in p27
kip1 expression than these agents alone.
Phosphorylation of p27
kip1 is the major regulatory mechanism
influencing the protein’s abundance. We therefore assessed the
level of phosphorylation on p27
kip1Ser10, which stabilises p27
during G1 arrest (Ishida et al, 2000). The MCF-7 2A cells
(Figure 3C) showed increased phosphorylation of p27
kip1Ser10 for
all treatments compared with androstenedione, although this was
most marked when considering AEE788þletrozole. Assessment of
BT474 A3 cells showed a more defined profile in which endocrine
agents alone had no effect on p27
kip1Ser10 phosphorylation, whereas
AEE788 in steroid-depleted medium or in combination with 4-OH
tamoxifen or letrozole markedly increased its phosphorylation.
On the basis of our previous observation that AEE788 seemed to
increase the percentage of cells in sub-G1, we investigated the
possibility that AEE788 induced apoptosis (Figure 3D). AEE788
had no effect on apoptosis in MCF-7 2A cells. In contrast,
AEE788±endocrine therapy significantly increased apoptosis
(Po0.001) in the BT474 A3 cell line. These data suggested that
the combination of AEE788 with endocrine therapy was most
effective in the ER
þ, HER2
þ cell line BT474 A3, particularly when
combined with oestrogen deprivation using letrozole.
AEE788 enhances ER transcriptional activity
BT474 A3 and MCF-7 A2 cells were transiently transfected with an
ERE-luciferase reporter construct and treated with 4-OH tamo-
xifen or letrozole±AEE788 (Figures 4A and B). In MCF-7 A2 cells,
the combination of drugs provided no further suppression of
ER-mediated transactivation compared with endocrine agents
alone, and this was confirmed in ZR75.1 A3 cells (data not
shown). Low concentrations of 4-OH tamoxifen and letrozole
seemed to increase ER-mediated transcription in MCF-7 A2 cells.
The reason for this remains unclear. Treatment of BT474 A3 cells
with AEE788 alone enhanced ER-mediated transactivation
compared with vehicle-treated control (Figure 4B). Increasing
concentrations of 4-OH tamoxifen reduced ER-mediated trans-
cription in a concentration-dependent manner but the combina-
tion of AEE788±4-OH tamoxifen enhanced ER transcription
compared with 4-OH tamoxifen alone at all concentrations tested.
Treatment with increasing concentrations of letrozole plus AEE788
suppressed ER-mediated transcription to the same degree as
letrozole alone at all concentrations tested.
To gain a broader perspective of the effect of AEE788±4-OH
tamoxifen or letrozole on ER-mediated transcription, the expres-
sion of two oestrogen-regulated genes, progesterone receptor
(PGR) and TFF1, was measured by quantitative reverse transcrip-
tase PCR in BT474 A3 cells (Figures 4C and D). Androstenedione
increased the expression of both target genes compared with the
steroid-depleted control. Both 4-OH tamoxifen and letrozole
suppressed expression. However, as seen with ER/ERE reporter
assays, AEE788 increased the expression of both genes. In
addition, AEE788 plus 4-OH tamoxifen showed a greater expres-
sion of the two genes compared with 4-OH tamoxifen alone. This
enhanced expression was much less pronounced for PGR and not
observed at all with TFF1 when AEE788 was combined with
letrozole. Further assessment showed that AEE788 alone or in
combination with endocrine agents also increased the expression
of ESR1 (Figure 4E) in keeping with our previous observations at
the protein level (Figure 2C).
The effect of AEE788 alone or in combination with
letrozole or tamoxifen on the growth of ZR75.1 A3
xenografts
In light of our in vitro data and the suggestion of a synergistic
interaction between AEE788 and endocrine therapy, we studied the
anti-tumour activity of AEE788±tamoxifen or letrozole in mice
bearing subcutaneous ZR75.1 A3 breast cancer xenografts. Initial
repeated measures analysis indicated that the growth patterns were
curved and not compatible with constant growth or shrinkage
(Figure 5). In every case, the estimated AEE788þletrozole
baseline-corrected tumour size was smaller. Multiple comparison-
corrected P-values for the 10-day AEE788þletrozole comparison
with the other groups were 0.0029 (vs vehicle control), 0.004
(AEE788), 0.351 (letrozole), 0.002 (tamoxifen) and 0.007
(AEE788þtamoxifen). Only in the case of the comparison with
letrozole did the difference with AEE788þletrozole fail to reach
statistical significance, although the trend was for the combination
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sto be more effective. The equivalent P-values at 24 days were
0.10, 0.97, 0.99, 0.31 and 0.53, respectively, indicating that, at
this later time point, the significant differences seen at 10 days
were lost.
DISCUSSION
On the basis of our increasing knowledge of the interactions
between ER and growth factor receptor signalling, there is a
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Figure 3 AEE788 in combination with 4-hydroxytamoxifen (4-OH) tamoxifen or letrozole enhances G1 arrest compared with monotherapy.
(A) Steroid-depleted MCF-7 A2 and (B) BT474 A3 cells were treated for 72h with vehicle, androstenedione (10nM), 10nM 4-OH tamoxifen or 10nM
letrozole±AEE788 (5mM for MCF-7 A2, or 0.5mM for BT474 A3 cells). Cell cycle was monitored by fluorescence-activated cell sorting analysis of cells
stained with propidium iodide (PI). Data are representative of two individual experiments. Bars represent ±s.e.m, *Po0.05, **Po0.01 are derived from the
comparison of endocrine agent alone vs the combination with AEE788 by Student’s unpaired t-test (C). Duplicate plates treated with drug combinations
were harvested after 24h treatment. Whole-cell extracts were probed for total and phosphorylated p27
Kip1 and cyclin D1. (D) Steroid-depleted MCF-7 A2
and BT474 A3 cells were treated for 24h with vehicle, androstenedione (10nM), 10nM 4-OH tamoxifen or 10nM letrozole±AEE788 (5mM for MCF-7 A2,
or 0.5mM for BT474 A3 cells). Apoptosis was measured using a Cell Death Detection ELISA PLUS kit (Roche). Data are expressed as fold increase in
apoptosis compared with that in the steroid-treated control. Bars represent ±s.e.m of triplicate wells *Po0.05, **Po0.01 are derived from the comparison
of endocrine agent alone vs the combination with AEE788 by Student’s unpaired t-test. Data are representative of two individual experiments.
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srationale for combining RTK inhibitors with endocrine therapy
in breast cancer, thus enhancing the efficacy of both agents
(Arpino et al, 2007). A number of clinical trials investigating this
concept have been reported and, although promising, it would
seem that only a small proportion of patients show benefit, hence
identification of the correct patient population is paramount
(Johnston, 2009). The aim of this study was to investigate the
predominantly anti-HER2 effects of AEE788 in combination with
tamoxifen or letrozole. Our preliminary in vitro analysis showed
that letrozole was superior at inhibiting the growth of cell lines
expressing ER compared with 4-OH tamoxifen, and this was
supported by our xenograft study. Of particular note is the fact that
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Figure 4 AEE788 enhances oestrogen receptor (ER) transcriptional activity. (A and B) Cell lines co-transfected with EREIItkLuc and pCH110 were
treated with a standard 10nM concentration of androstenedione and log10(M) increasing concentrations of 4-hydroxytamoxifen (4-OH) tamoxifen or
letrozole in the absence or presence of AEE788 (5mM for MCF-7 A2 and 0.5mM for BT474 A3). Luciferase activity was normalised by b-galactosidase from
cotransfected pCH110. Normalised luciferase activity from quadruplicate wells was expressed relative to that of the vehicle-treated control. Bars represent
±s.e.m. *Po0.05, **Po0.01, are derived from the comparison of the endocrine agent alone vs the combination with AEE788 by Student’s unpaired t-test.
Effects were confirmed in two independent experiments. (C) Cells were treated with a standard concentration of androstenedione (10nM) alone or in
combination with 10nM 4-OH tamoxifen or 10nM letrozole±0.5mM AEE788. Quantitative reverse transcriptase PCR was used to measure the expression
of TFF1,( D) progesterone receptor (PGR) and (E). ESR1. Bars represent ±s.e.m.
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sletrozole also reduced the growth of HER2-amplified BT474 A3 cells
in vitro, in keeping with previous clinical observations that HER2
þ
breast cancer seems to be more sensitive to oestrogen deprivation
than to tamoxifen (Ellis et al,2 0 0 1 ;D o w s e t tet al,2 0 0 5 ) .
Submicromolar concentrations of AEE788 induced significant
growth inhibition in both BT474 A3 and SKBR3 A3 cells in vitro,
whereas MCF-7 A2 and ZR75.1 A3 were 20-fold less sensitive in
keeping with their relative HER2 expression. AEE788 plus either
letrozole or 4-OH tamoxifen showed synergy, providing enhanced
growth suppression compared with monotherapies. This was most
notable in BT474 A3 cells. We postulate that the increased
sensitivity of this cell line to the combination of 4-OH tamoxifen or
letrozole with AEE788 is reflective of their increased HER2
expression compared with MCF-7 A2 and ZR75.1 A3.
The lack of any interaction between AEE788 and 4-OH tamoxifen
or letrozole in ER-negative SKBR3 A3 cells suggested that the synergy
seen in BT474 A3 cells might be explained by their dual expression of
HER2 and ER. Previous studies suggest that elevation of pAKT and
pERK1/2 as a result of increased HER2 signalling reduces sensitivity
to endocrine agents (Arpino et al, 2008). This can occur through
downregulation of ER, ligand-independent activation, or in the case of
resistance to tamoxifen, preferential recruitment of coactivators as
opposed to corepressors to tamoxifen-bound ER (Shou et al, 2004). It
has been demonstrated that inhibition of HER2 signalling with
gefitinib in combination with tamoxifen restores corepressor recruit-
ment (Shou et al, 2004). These studies allude to the ability of EGFR/
HER2 signal transduction pathways to modulate ER phosphorylation
and recruitment or assembly of the basal transcription machinery.
The ERE reporter assays showed that the combination of AEE788
with 4-OH tamoxifen or letrozole provided no further suppression of
ER-mediated transcription compared with endocrine agents alone in
either MCF-7 A2 or ZR75.1 A3 cells. This was not unexpected, as
these cell lines are dependent on ER signalling for their proliferation.
In contrast, ER/ERE-dependent transcription in BT474 A3 cells
treated with AEE788±4-OH tamoxifen was enhanced compared with
4-OH tamoxifen alone. This increase in transactivation, however, was
not observed with letrozole. Parallel data were obtained on the
expression of two endogenous ER-regulated genes TFF1 and PGR.
One potential explanation may be attributed to the relative increase
in ER-a levels seen in BT474 A3 cells when treated with AEE788 in
combination with endocrine therapy. These results indicate that in
naturally HER2/ER-expressing tumours, increased oestrogen signal-
ling may occur as a result of inhibiting the growth factor signalling
p a t h w a ya n d ,c o n v e r s e l y ,i n c r e a s ed growth factor signalling may
result as a consequence of inhibiting oestrogen signalling. The exact
mechanism remains unclear. However, recent studies have implicated
the forkhead box transcription factor FOXO3A, which is capable of
mediating ER/ERE transactivation. In a recent study, lapatinib was
shown to downregulate AKT, removing the repression of FOXO3A
and activating ER transcription (Xia et al, 2006). It could be
hypothesised that this, coupled with the elevated levels of ER seen in
our study, would be sufficient to drive ER-mediated transcription.
Hence, although BT474 cells are HER-2 dependent and HER2 RTK
inhibitors suppress proliferation, treatment can lead to increased ER-
driven transcription and may provide an escape mechanism. This
provides yet further rationale for the combined use of RTK inhibitors
with letrozole in patients with ER
þHER2
þ breast cancer.
The observation that AEE788 in combination with endocrine
therapy suppressed proliferation and was associated with decreases
in ERK1/2 and AKT led us to investigate the effect on cell-cycle
progression. We showed in BT474 A3 cells that AEE788 alone led to
a significant sub-G1/G1 arrest and a corresponding decrease in
S-phase, which was further enhanced by both 4-OH tamoxifen and
letrozole. This observation was similarly seen in MCF-7 A2 cells,
although to a lesser degree. It is well established that G1 arrest
requires an effective kinase inhibitor protein function (Boehm et al,
2002). Hence, we assessed the effect of the drug combinations on
cyclin D1 and p27
Kip1.p 2 7
Kip1 is necessary for anti-oestrogen-
mediated cell-cycle arrest, and studies have shown that enhanced
expression of HER2 can lead to the deregulation of p27
Kip1, leading
to anti-oestrogen resistance (Donovan et al, 2001; Lenferink et al,
2001). In this setting, HER2 activates ERK1/2 and AKT, altering the
phosphorylation of p27
Kip1, thus decreasing its susceptibility to
protein degradation (Liang et al,2 0 0 2 ;S h i net al,2 0 0 2 ) .W ea s s e s s e d
the phosphorylation status of p27
Kip1 in MCF-7 A2 and BT474 A3
cells treated with AEE788 alone or in combination. Phosphorylation
of p27
Kip1 Ser10 (which targets p27
Kip1 for accumulation) in MCF-7
2A cells was increased under all treatment conditions when
compared with androstenedione, although this was most notable
for the combination of letrozoleþAEE788. Similarly, BT474 A3
cells showed high levels of p27
Kip1Ser10 in response to AEE788
alone or in combination. These alterations in phosphorylation of
p27
Kip1Ser10 largely mirrored the changes in pAKT. Correspondingly,
in BT474 A3 cells, cyclin D1, a transcription target of ER (Sabbah
et al, 1999), was also suppressed by AEE788, alone and
in combination, confirming growth inhibition.
Assessment of tamoxifen and letrozole±AEE788 in the ZR75.1
A3 xenograft model showed that letrozole as a monotherapy seemed
superior to tamoxifen at inhibiting tumour growth, consistent with
recent clinical observations that AIs are superior to tamoxifen (Ellis
et al, 2001; Thu ¨rlimann et al, 2005). Rather surprisingly, tamoxifen
in combination with AEE788 was also less effective than letrozole
alone. Indeed, letrozole as a monotherapy was not significantly less
potent than AEE788 combined with letrozole. This may be explained
by the fact that ZR75.1 A3 cells use the ER signalling pathway
predominantly for growth in this setting.
Overall, these observations suggest that oestrogen deprivation
in combination with AEE788, or similar EGFR/HER2 inhibitors,
m a yb es u p e r i o rf o rt h et r e a t m e n to fb o t hde novo and acquired
ER
þ, HER2
þ endocrine-resistant breast cancer and may also show
potential mechanisms through which resistance to therapy may arise.
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Figure 5 AEE788 in combination with letrozole is more effective
at reducing tumour volume compared with either treatment alone. ZR75.1
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